REPORT ID 8682

United States Antidiabetic Thiazolidinediones Market Report 2017

Publish Date
9-Nov-17
Pages
98
Format
Electronic (PDF)

In this report, the United States Antidiabetic Thiazolidinediones market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Antidiabetic Thiazolidinediones in these regions, from 2012 to 2022 (forecast).

United States Antidiabetic Thiazolidinediones market competition by top manufacturers/players, with Antidiabetic Thiazolidinediones sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Sanofi
    Takeda Pharmaceuticals
    Eli Lilly
    Merck & Co.
    Novo Nordisk
    Bristol-Myers Squibb
    Pfizer
    AstraZeneca
    GlaxoSmithKline
    Boehringer Ingelheim

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Rosiglitazone
    Pioglitazone
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospitals
    Clinics
    Other

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Antidiabetic Thiazolidinediones Market Report 2017
1 Antidiabetic Thiazolidinediones Overview
    1.1 Product Overview and Scope of Antidiabetic Thiazolidinediones
    1.2 Classification of Antidiabetic Thiazolidinediones by Product Category
        1.2.1 United States Antidiabetic Thiazolidinediones Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Antidiabetic Thiazolidinediones Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Rosiglitazone
        1.2.4 Pioglitazone
    1.3 United States Antidiabetic Thiazolidinediones Market by Application/End Users
        1.3.1 United States Antidiabetic Thiazolidinediones Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Other
    1.4 United States Antidiabetic Thiazolidinediones Market by Region
        1.4.1 United States Antidiabetic Thiazolidinediones Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Antidiabetic Thiazolidinediones Status and Prospect (2012-2022)
        1.4.3 Southwest Antidiabetic Thiazolidinediones Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Antidiabetic Thiazolidinediones Status and Prospect (2012-2022)
        1.4.5 New England Antidiabetic Thiazolidinediones Status and Prospect (2012-2022)
        1.4.6 The South Antidiabetic Thiazolidinediones Status and Prospect (2012-2022)
        1.4.7 The Midwest Antidiabetic Thiazolidinediones Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Antidiabetic Thiazolidinediones (2012-2022)
        1.5.1 United States Antidiabetic Thiazolidinediones Sales and Growth Rate (2012-2022)
        1.5.2 United States Antidiabetic Thiazolidinediones Revenue and Growth Rate (2012-2022)

2 United States Antidiabetic Thiazolidinediones Market Competition by Players/Suppliers
    2.1 United States Antidiabetic Thiazolidinediones Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Antidiabetic Thiazolidinediones Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Antidiabetic Thiazolidinediones Average Price by Players/Suppliers (2012-2017)
    2.4 United States Antidiabetic Thiazolidinediones Market Competitive Situation and Trends
        2.4.1 United States Antidiabetic Thiazolidinediones Market Concentration Rate
        2.4.2 United States Antidiabetic Thiazolidinediones Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Antidiabetic Thiazolidinediones Manufacturing Base Distribution, Sales Area, Product Type

3 United States Antidiabetic Thiazolidinediones Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Antidiabetic Thiazolidinediones Sales and Market Share by Region (2012-2017)
    3.2 United States Antidiabetic Thiazolidinediones Revenue and Market Share by Region (2012-2017)
    3.3 United States Antidiabetic Thiazolidinediones Price by Region (2012-2017)

4 United States Antidiabetic Thiazolidinediones Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Antidiabetic Thiazolidinediones Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Antidiabetic Thiazolidinediones Revenue and Market Share by Type (2012-2017)
    4.3 United States Antidiabetic Thiazolidinediones Price by Type (2012-2017)
    4.4 United States Antidiabetic Thiazolidinediones Sales Growth Rate by Type (2012-2017)

5 United States Antidiabetic Thiazolidinediones Sales (Volume) by Application (2012-2017)
    5.1 United States Antidiabetic Thiazolidinediones Sales and Market Share by Application (2012-2017)
    5.2 United States Antidiabetic Thiazolidinediones Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Antidiabetic Thiazolidinediones Players/Suppliers Profiles and Sales Data
    6.1 Sanofi
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Sanofi Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Takeda Pharmaceuticals
        6.2.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Eli Lilly
        6.3.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Eli Lilly Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Merck & Co.
        6.4.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Merck & Co. Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Novo Nordisk
        6.5.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Novo Nordisk Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Bristol-Myers Squibb
        6.6.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Bristol-Myers Squibb Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Pfizer
        6.7.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Pfizer Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 AstraZeneca
        6.8.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 AstraZeneca Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 GlaxoSmithKline
        6.9.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 GlaxoSmithKline Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Boehringer Ingelheim
        6.10.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Boehringer Ingelheim Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview

7 Antidiabetic Thiazolidinediones Manufacturing Cost Analysis
    7.1 Antidiabetic Thiazolidinediones Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Antidiabetic Thiazolidinediones

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Antidiabetic Thiazolidinediones Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Antidiabetic Thiazolidinediones Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Antidiabetic Thiazolidinediones Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Antidiabetic Thiazolidinediones Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Antidiabetic Thiazolidinediones Sales Volume Forecast by Type (2017-2022)
    11.3 United States Antidiabetic Thiazolidinediones Sales Volume Forecast by Application (2017-2022)
    11.4 United States Antidiabetic Thiazolidinediones Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer